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[57] ABSTRACT 
A process for preparing bromine-containing dyes la 
belled with gamma-emitting isotopes of bromine, and 
the product thereof which is useful as an imaging agent 
for the hepato-biliary system, particularly in dynamic 
imaging methods. The dyes prepared are from the class 
of triarylmethane dyes, and also from the phthalein 
subclass of the class of xanthene dyes, and the labelling 
thereof is effected with 76Br, 77Br or 82Br. The process 
for preparing these dyes involves reacting the non 
brominated dye precursor with either 76Br;, 77Br; or 
82BI‘2. This is a substitution type of reaction in which a 
ring hydrogen is substituted by either 76Br, 77Br or 32Br. 
11 Claims, 2 Drawing Figures 
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SYNTHESIS ANDUSE OF DIAGNOSTIC 
RADIO-PHARMACEUTICALS COMPRISING 
RADIOACTIVE ISOTOPES OF BROMINE WITH 
DYES' 
FIELD'OF THE INVENTION 
This invention relates to a process for making bro 
mine-containing dyes labelled ‘with gamma-emitting 
isotopes of bromine, and the product thereof which is 
useful as a diagnostic radio-pharmaceutical. More par 
ticularly, the invention is concerned with the procedure 
employed for synthesizing said dyes labelled with gam 
ma-emitting isotopes of bromine, which involves pre 
cautions for minimizing the exposure of personnel to 
damaging levels of harmful radiation. Also, the inven 
tion is particularly concerned with ‘the use of a diagnos 
tic radiopharmaceutical product which is far superior to 
presently known products employed in diagnostic nu 
clear medicine as imaging agents for the hepato-biliary 
system to visualize abnormalities and to determine the 
function thereof by dynamic imaging. ' 
THE PRIOR ART 
Related Diagnostic Radiopharmaceutical Products Of 
The Prior Art Which Are Useful As Imaging Agents 
For The Hepato-biliary System 
The drug which has been most widely used in the 
diagnosis of liver malfunction and measurement of 
hepato-biliary function in nuclear medicine is a radioac 
tive dye, i.e., Rose Bengal in which the iodine substitu 
ents are of the 1311 type. This dye is prepared in high 
yield by an exchange reaction. The procedure involves 
re?uxing Rose Bengal in acid form with radio-iodine 
(Na"‘I and oxidizing agent) overnight to carry out an 
exchange type of reaction. The radioiodinated Rose 
Bengal acid is precipitated with acid, washed with wa 
ter, and, by treatment with sodium hydroxide, is formu 
lated as the sodium salt. This material can then be steril 
ized by autoclaving or sterile ?ltration. The product is 
stable when formulated with propylene glycol and 
stored at refrigerated temperatures. 
Another drug suggested as a potential hepato-biliary 
imaging agent is dibromo-estrone, in which the bromine 
substituents are 77.Br. Spicer et a1, Int. J. Appl. Rad. 2nd 
Isot, Vol. 28, pp. 163-168 (1977) have suggested that 
77Br-2,4-dibromoestrone may be a tracer of potential 
value for liver and gallbladder function studies. 
U.S. Pat. No. 3,928,552 to Winchell et al, issued Dec. 
23, 1975, is directed to a radiopharmaceutical compris 
ing Z-mercaptoisobutyric acid chelating reduced tech 
netium-99m for scintigraphically imaging the liver and 
biliary tract morphology and function. ' 
U.S. Pat. No. 3,981,980’to Baker et al, issued Sept. 21, 
1976, is directed to a diagnosticsubstance for cholescin 
tigraphy which is formed by the reaction of pyridoxal 
and amino acids labelled with a radionuclide, in pyro 
gen-free water, the reaction product being adjusted to a 
pH of 8 to 9 and then autoclaved and cooled'to produce 
a sterile, pyrogen-free non-antegenic solution for injec 
tion for biliary scanning. 
Comparison With Presently Employed Products Used 
In Diagnosis Of Liver Function And Measurement of 
Hepato-biliary Function In Nuclear Medicine 
As noted above, the drug most widely used in the 
diagnosis of liver malfunction and measurement of 
hepato-biliary function in nuclear medicine today is 
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Rose Bengal-1311. This particular isotope, because of the 
emission of particulate matter v(B f), is not ideally suited 
for use in humans. The consequences of the use of B" 
emitting radiopharmaceuticals include: 
(a) The dose must be very low; 
(b) Preparations which contain excessive 1311 as the 
iodide can endanger the thyroidbecauseiodide is 
concentrated in, this organ; 
(0) The drug is cleared from the blood at a relatively 
slow rate (8-10 min. half life for Rose Bengal com 
pared with 1.5 min. for bromphenol blue).' 
The rate of blood clearance becomes important in 
considering the length of time one must wait after injec 
tion prior to imaging. ' ’ ‘ 
' There ‘is an' alternative iodine label (Iodine-123) 
which like bromine-77 is cyclotron produced. This 
isotope does not decay by emission of particulate mat 
ter, but has a single 'y ray of 0.16 Mev. The major draw 
back is that iodine-123 has a short half life (13 hours). 
This limitation in half life would necessitate the in 
house production of radiopharmaceuticals labelled with 
iodine-123; this limits its use to facilities which are phys 
ically close to a cyclotron. Bromine-77, however, due 
to its relatively long half life (56 hours) can be produced 
at the cyclotron site, incorporated into a radiopharma 
ceutical, shipped anywhere vin the country, and stored 
for several days before use. 
‘ An alternative method for estimating hepato-biliary 
function is the use of contrast agents and X-rays. In this 
type of diagnostic procedure, the patient ingests a large 
dose (600 mg) of drug and after 12 ‘hours undergoes 
exposure to an external source of radiation. The disad 
vantages of this procedure are: ' 
(a) Large dose of drug; the contrast agents are known to 
have speci?c toxicosis; ' 
(b) The patient receives a much larger dose of radiation 
(a single X-ray exposes the patient to a greater dose 
than the total exposure of the radioactive dye); 
(c) The diagnosing physician gets much less information 
to work with. " 
For example, the X-ray procedure gives one or two 
points in time, while the nuclear medicine technique can 
give dynamic data involving literally thousands of data 
points over a period of time. It should be re-emphasized 
that the radiation technique exposes the patient to a 
much higher dose of radiation for one data point than 
the nuclear medicine technique does for thousands of 
data points.’ - 
\OBJECTS THE INVENTION 
.An object of the present invention is to provide a 
process for- producing a diagnostic radiopharmaceutical 
product labelled with a radioactive halogen by a substi~ 
tution type of reaction not previously employed in the 
prior art, and which is simpler to carry out than the 
prior art processes involving exchange reactions. 
Another object of the present invention is to provide 
a diagnostic radiopharmaceutical product labelled with 
a radioactive halogen which does not have the disad 
vantages of the products previously employed in the 
prior art for hepatic-biliary morphology and function 
studies. 
A further object of the'invention is to provide a 
method for using the diagnostic radiopharmaceutical 
product of the invention in. nuclear medicine tech 
niques. 
4,256,727 
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These and other objects and advantages of the pres 
ent invention will become apparent to those skilled in 
the art from a consideration of the following speci?ca 
tion and claims, taken in conjunction with the accompa 
nying drawings. 
GENERAL DESCRIPTION OF THE INVENTION 
The starting material is the immediate precursor of 
the ?nally desired dye containing no bromine. For ex 
ample, if the ?nally desired dye is tetrabromophenol 
phthalein in which the four bromine atoms are either 
76Br, 77Br or “Br, then the starting material is the well 
known phenolphthalein. The ?nally desired dye must of 
course be already known to be one which is excreted to 
a large extent in bile in a number of animal species. The 
synthesis occurs through the reaction of 76Br2, 77Br2 or 
82Brz in glacial acetic acid or'any other suitable inert 
reaction medium with said immediate precursor of the 
dye containing no bromine. The radioactive product is 
recovered from the reaction mixture by evaporation of 
the reaction medium containing it, separated by selec 
tive extraction, and puri?ed by column chromotogra 
phy or other suitable procedure. 
DETAILED DESCRIPTION OF THE 
INVENTION 
A more complete understanding of the procedures 
I and products of the present invention may be had by 
reference to theaccompanying drawings in which 
FIG. 1 is a schematic flow diagram of the processes 
of the invention setting forth the preferred modes of 
operation. ' 
FIG. 2 illustrates an apparatus suitable for carrying 
out the process shown in FIG. 1. 
The flow diagram of FIG. 1 mentions certain speci?c 
reactants and procedural steps which are the most desir 
able in carrying out the present invention. Other reac 
tants and procedural steps can be employed, however, 
as will be explained more fully in a later section of this 
speci?cation. For instance, although the ?ow diagram 
refers speci?cally to the use of 76Br2, 77Br2 or 82Br; as 
the brominating agent for the dye precursor com 
pound,the use of other gamma-emitting isotopes of Br2 
is feasible. ' 
In the starting stage of this flow diagram there is 
given, as an example of a suitable dye precursor com 
pound, phenolphthalein. All of the dyes in the following 
Table cari be prepared by the process of this invention. 
They are shown in their ?nal brominated form, includ 
ing tetrabromophthalein. The starting compounds are, 
of course, the same as the ?nal dye compounds except 
that they are not brominated in any position. 
TABLE I 
/° @ 
Br 3 
HO c -- (|)\0 
Br 
Br Br 
OH 
Bromphenol Blue: 4,4'-(3I-I-2,l,-benzoxathiol-3-ylidene) 
bis[2,6-dibromophenol]S,S,-dioxide 
25 
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TABLE I-continued 
/O 
\ 0 
Br S 
I 
HO C '— 0 
CH3 
Br CH3 
OH 
Bromcresol purple: 4,4'-(3H-2,1-benzoxathiol-3-ylidene) 
bis[2-bromo-6-methylphenol]S,S-dioxide ' 
/0 
Br CH3 5 
I \O 
HO ' C — 0 
CH3 
Br 
Br Br 
01-! 
Bromcresol green: 4,4'-(3H-2,l-benzoxathiol-3-ylidene) 
bis[2,6-dibromo-3-methylphenol]S,S-dioxide ‘ 
Ethyl Eosin: 2',4’,5',7',-tetrabromo?uorescein ethyl ester 
Cl 
Br Br 
Tetrabromophenolphthalein: 3,3-Bis-(3,5-dibromo-4 
hydroxy-phenylyl(3l-I)-isobenzofuranone 
0 
Sulfobromophthalein sodium (BSP): 5,5'-(4,5,6,7 
tetrabromo-J-oxo-l (3H)-isobenzofuranylidene) 
4,25 6,727 
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TABLE I-continued 
bis[2-hydroxybenzenesulfonic acid] 
disodium salt 
Eosine I bluish: 4',5’-dibromo-3',6’-dihydroxy-Z', 
7'-dinitro spiro[isobenzofuran-l(3I-I),9'[9H]xanthen]-3 
one disodium salt 
Bromlhymol Blue: 4,4'-(3H-2,l~benzoxathiol-3-ylidene)bis 
[2-bromo-3-methyl-6-(l-methylethyl)phenol]S,S-dioxide 
0 
Br CH3 5%0 
l 
I-IO C - 0 
CH3 
CH3 
CH3 Br 
OI-I 
Bromoxylenol Blue: 
Br 
0H 
Bromophenol Red: 
0 
O 
/ COZNa 
Br Br 
\ 
\ 
no 0 \o 
Br Br 
Eosine Yellowish: 2',4’,5’,7’-tetrabromo?uorescein 
Preferably the reaction is carried out in an inert or 
ganic reaction medium, such as glacial acetic acid, in 
which the dye precursor compound is placed. The reac 
tant bromine, i.e., 76BI‘2, 77Br2 or 82Br; , is in either the 
gaseous or liquid state. It is preferably introduced into 
the reaction mixture in the gaseous state through some 
kind of gas dispersing means. Introduction of the reac 
tant bromine gas in this manner effects sufficient agita 
tion of the reaction mixture to avoid the necessity of any 
other kind of agitation, although this may, of course, be 
done if so desired. With respect to the bromine reactant, 
if 82Br; is chosen, it can be supplied directly as it is 
commercially available. Since 77Br2 is not commercially 
15 
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available, it must be generated from K77Br, in a manner 
such as is described by Slaunwhite and Neeley, Analyti 
cal Biochemistry, Vol. 5, page 133 (1963). 
The reaction vessel containing the reaction mixture is 
disposed in a leaded fume hood and can be heated in any 
desired manner, but it is preferred to do this by immer 
sion in an oil bath maintained at the desired reaction 
temperature. The heating is carried out at a temperature 
and for a time period suf?cient to effect the desired 
bromination reaction. The temperature may be in the 
range of from about 110° C. to 125° C. Thetime of reac 
tion may be in the range of from about 4 hours to 12 
hours. Since HBr is formed as a by-product of the bro 
mination reaction, it is vented from the reaction vessel, 
and passed serially through two NaOH containing traps 
wherein it is neutralized to form NaBr. Since this is 
radioactive, it can be disposed of in any suitable and 
approved manner. 
After the reaction has been completed, the reaction 
vessel is flushed with nitrogen gas to remove HBr, and 
the solvent is removed by evaporation. The reaction 
vessel is then removed from the oil bath, preferably by 
the use of tongs, but maintained disposed in the leaded 
fume hood. While still in the hood, the contents of the 
reaction vessel are removed, and then subjected to a 
separation procedure such as selective extraction in 
order to recover the dye compound labelled with the 
radioactive bromine. Thereafter, and while still being 
maintained within the leaded fume hood, the dye com 
pound is subjected to a purification procedure, e.g., 
column chromatography. 
As stated above, FIG. 2 illustrates an apparatus ar 
rangement suitable for carrying out the process set forth 
in the ?ow sheet of FIG. 1. ' 
If 77Br2 is employed in the apparatus of FIG. 2, then 
the 77Br2 source consists of a 77Br2 generator which 
converts 77Br" to 77B1'2. This has been previously de 
scribed by Slaunwhite and Neeley, utilizing manganese 
dioxide as the oxidizing agent. The 77B1'; is distilled into 
the reaction mixture and then the reaction vessel is 
sealed. 
The following Examples are given merely as illustra 
tive of the present invention and are not to be consid 
ered as limiting. 
EXAMPLES OF THE INVENTION» 
Example 1 
Synthesis'of Bromphenol Blue Labelled With 77Br 
Starting Material: 
HO 
OH 
The above starting compound and glacial acetic acid 
were added to a reaction vessel disposed in an oil bath, 
4,256,727 
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all of which were placed in a leaded fume hood. There 
after, 77Br; in gaseous form was supplied to the reaction 
vessel. Then the reaction vessel was heated in the oil 
bath at 123° C. and the reaction was completed in about 
4-24 hours. 
After the reaction was completed, the reaction vessel 
was flushed with nitrogen gas to remove HBr, and the 
solvent was removed by evaporation. The reaction 
vessel was then removed from the oil bath, preferably 
by the use of tongs. Thereafter, and while still in the 
leaded fume hood, the contents of the reaction vessel 
were removed and selectively extracted to recover the 
desired product, i.e., the dye compound labelled with 
radioactive bromine, which was then puri?ed by col 
umn chromotography. The product had the formula: 
0 
Br / 
ISAC 
HO C —— 0 
Br 
“Br Br 
OH 
This‘product was diluted with an aqueous buffer, and 
then stored in a lead container in the leaded fume hood 
in which it had been prepared. 
Examples 2-1 3 
The procedure set forthin Example 1 above was car 
ried out, but employing as the starting material in each 
example, the immediate precursor compound contain 
ing no bromine but otherwise corresponding to the 
compounds listed as entries 2-13 Table I above. The 
reaction temperature and time of reaction were varied 
as required to obtain the desired product. The products 
obtained by these Examples 2-13 correspond to entries 
2 to 13 in said Table I above. 
MODIFICATIONS AND EQUIVALENTS 
With respect to the dyes which are labelled with 
radioactive 76Br, 77Br or 82Br, this invention is not lim 
ited to the speci?c dyes disclosed in the foregoing de 
scription. Thus, these speci?c dyes can be modi?ed so 
that the bromine substituents can be at positions other 
than those speci?cally shown. 
In addition, the dyes which are labelled with radioac 
tive 76Br, 77Br or 82Br and which can be prepared by 
this invention are not limited to the classes of dyes 
shown in the foregoing description. Any known bro 
mine-containing dye which is excreted to a large extent 
in the bile of a number of animal species is suitable if it 
is labelled with 76Br, 77Br or 32Br, i.e., if the non-radi 
oactive Br substituents are replaced by 76Br, 77Br or 
82Br in part or in whole. 
Finally, with respect to the dyes which are taught as 
labelled with radioactive 76Br, 77Br or 1'32Br, thisinven 
tion is not limited to the use of these three bromine 
isotopes. Any gamma-emitting isotope of bromine can 
be employed. 
Moreover, although the flow diagram of FIG. 1 
shows the reaction as being carried out in glacial acetic 
acid, there are many other inert reaction media which 
10 
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are suitable for this purpose. Examples thereof are lactic 
acid and propionic acid. In general, any acidic media in 
which the brominating agent and the precursor dye are 
soluble are suitable. 
The flow diagram of FIG. 1 shows the reaction vessel 
being heated by immersion in an oil bath. Many other 
variants for such heating are available. For example, the 
reaction vessel can be jacketed, and a heat exchange 
liquid circulated therethrough. An alternative is the use 
of an electrically heated resistance wire wrapped 
around the exterior of the reaction vessel. 
Next, the flow diagram of FIG. 1 teaches separation 
of the dye compound from the reaction mixture by 
evaporation of the reaction medium followed by selec 
tive extraction. This, of course, could be varied in many 
ways. For example, chromatographic techniques such 
as tlc and hplc, etc., are suitable. 
Further, the flow diagram of FIG. 1 shows puri?ca 
tion of the dye compound by column chromatography. 
Other procedures such as recrystallization, etc. are also 
suitable. 
An alternative synthesis in which the starting mate 
rial is the relatively inexpensive bromide anion (76Br—, 
77Br‘, or 82Br—) can be ,carried out. Speci?cally, a 
solution of the alkali salt of the appropriate isotopic 
bromide is added to an acidic solution of potassium 
bromate and the speci?c precursor dye. The resultant 
solution is extracted into benzene, and the extract 
worked up in a similar fashion to that described in Ex 
ample 1 for the reaction mixture containing the labelled 
dye. 
USE IN PATIENTS ' 
The selected dye labelled with a gamma-emitting 
isotope of bromine, i.e., 76Br, 77Br or 82Br, is injected 
intravenously into the patient. Following injection, the 
liver and biliary system are monitored using equipment 
which maps radioisotope distribution within the human 
body. Digital data can also be stored on magnetic tape, 
allowing computer processing to provide graphs show 
ing activity variations with time in selected areas of the 
scan (liver, gallbladder, intestine, etc.). 
Distribution studies of the labelled dye after intrave 
nous injection show initial rapid clearance of the radio 
activity from the blood, speci?cally by the liver, with 
subsequent, almost complete, excretion into the biliary 
tract. Stated otherwise, the labelled dye of this inven 
tion rapidly accumulates in the liver, and then is ex 
creted from the liver to the biliary tract, so as to be 
useful for hepatic-biliary morphology and function 
studies. 
The monitoring equipment to be employed is well 
known in the art. One type of monitoring equipment 
found to be particularly useful for the purposes of this 
invention is of the scanning type, i.e., the scanning head 
thereof is caused to trace an interlaced pattern which 
covers the area of the body which is of interest. One 
example of such equipment 'is that described in US. Pat. 
No. 3,509,341 to Hindel et al, issued Apr. 28, 1970. In 
this system there is provision for storing the scanning 
data on magnetic tape for any desired use. 
If it is desired to use monitoring equipment of the 
camera type, i.e., stationary with respect to the human 
body, but which can be‘employed to monitor speci?c 
areas of the human body, then US. Pat. No. 3,983,394 
to Martone et al, issued Sept. 28, 1976, is of particular 
interest. In this system there is provided window gener 
4,256,727 
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ating circuitry for de?ning a window in the detector 
?eld of view, and for gating to an output an indication 
of only those stimuli occurring within the window. This 
enables a very precise monitoring of a speci?c organ in 
the human body to be carried out. 
The system described in US. Pat. No. 3,308,438 to 
Spergel et a1, issued Mar. 7, 1967, is of particular interest 
with respect to the dynamic imaging studies referred to 
above. In this system radiation data are accumulated for 
a short period of time and then destructively read out of 
the memory and displayed on a cathode ray tube at 
selected rates. Such a system has numerous advantages, 
e. g., an immediate and accurate presentation of the 
monitored subject may be observed, in detail as the 
actual events occur, or the system may be employed to 
provide permanent records ‘for subsequent study as 
desired. I’ ', . 
The [invention being .thus, described, it willbe obvious 
that the same may be variedin many ways. Such varia 
tions are not to be regarded as ‘a departure from the 
spirit and scope of the invention, and all such modi?ca 
tions are intended to be included within the scope of the 
following claims. 
What is claimed is: 
1. A process for imaging the liver or biliary tract of a 
patient comprising the steps of: 
intravenously injecting the patient with a dye labelled 
with a gamma-emitting isotope of bromine; and 
then scintigraphically imaging the liver or biliary 
tract of the patient. 
2. A process as recited in claim 1 in which the gam 
ma-emitting isotope of bromine is selected from the 
group consisting of 76Br, 77Br and 82Br. 
3. A process for serially imaging the liver and biliary 
tract of a patient comprising the steps of: 
intravenously injecting the patient with a dye labelled 
with a gamma-emitting isotope of bromine; and 
then scintigraphically imaging the liver and biliary 
tract to follow the movement of radioactivity into 
the liver and then from it’ through the biliary tract. 
4. A process as recited in claim 4 in which the gam 
ma-emitting isotope of bromine is selected from the 
group consisting of 76Br, 77Br and 82Br. 
5. A process for imaging the liver or biliary tract of a 
patient comprising the steps of: 
intravenously injecting the patient with a dye se 
lected from the group consisting of triarylmethane 
dyes and the phthalein subclass of the class of Xan 
thene dyes, said dye being labelled with a gamma 
emitting isotope of bromine; and then scintigraph 
ically imaging the liver or biliary tract of the pa 
tient. 
6. A process as recited in claim 5 in which the gam 
ma-emitting isotope of bromine is selected from the 
group consisting of 76Br, 77Br and 82Br. 
7. A process as recited in claim 5 in which the gam 
ma-emitting isotope of bromine is 77Br. 
8. A process as recited in claim 5 in which the dye 
labelled with a gamma-emitting isotope of bromine has 
the structural formula: 
25 
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XI 
wherein 
X1 is Br or CH3, 
. X2 is Br or CH3,v 
X7 is Br or H, and 
XgiSBI‘OI'H, ' ‘ - "' 
with the proviso that X1 and X2 must be the same; with 
the additional proviso that when X] and X; are Br, then 
X3_6 is H, and X7 and X8 are Br or H; with the further 
proviso that when X1 and X; are CH3 , then X3_6 is H 
and X7 and X3 are Br; with the still further proviso that 
when X3_6 is Br, then X1 ,X2 ,X7 and X3 are Br; and with 
the final proviso that the Br substituents are gamma 
emitting isotopes. 
9. A process as recited in claim 8 in which the dye 
labelled with a gamma-emitting isotope of bromine has 
the structural formula: 
0 
Br / 
s——>o 
1 
HO C ——- 0 
Br 
Br Br 
OH 
in which the Br substituents are 77Br. 
10. A process as recited in claim 5 in which the dye 
labelled with a gamma-emitting isotope of bromine has 
the structural formula: 
X5 ‘III, 
X1 X7 C 
‘a’ 
C OH 
X6 
X5 
X2 
X4 X3 
OH 
wherein 
X1 is Br or SO3Na, 
X2 is Br or H, 
X3 is Br or H, 
the structural formula: 1 
4,256,727 
11 _ 12 
X4 is Br 01' SO3Na, and X4 
. X5 X3 
X54; is Br or H, 5 
. . X6 X1 
with the proviso that X] and X4 must be the same; with Br B 
\ r 
the additional proviso that when X1 and X4 are SO3Na, 1o \ 
. X2 0 \0 
then X; and X3 are H and X5_g is Br; and with the ?nal Br Br 
proviso that the Br substituents are gamma-emitting 15 WESIZHCOZCHZCH3 or COzNa, 
‘ X2 is OH or NaO, and 
isotopes. ' , X3_6 is C] or H, , 
with the proviso that when X1 is CO2CH2CH3, ‘then X2 
is OH and X3_6 is H; with the additional proviso that 
20 when X1 is COzNa and X3_6 is Cl, then X; is NaO; with 
_ , _ _ , the further proviso that when X] is COzNa and X3_6 is 
labelled with a gamma-emitting lsotope of bromine has H, then X2 is OH; and with the ?nal proviso that the B1. 
substituents are gamma-emitting isotopes. 
* $ t ‘ i 
11. A process as recited in claim 5 in which the dye 
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